产品
编 号：F191838
分子式：C16H17NO5
分子量：303.31
分子式：C16H17NO5
分子量：303.31
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1607803-67-7
产品详情
生物活性：
B I09 is an IRE-1 RNase inhibitor, with an IC50 of 1230 nM.
体内研究：
B I09 has a halflife of approximately 1.5 hours and reaches its peak concentration of approximately 39 μM in mouse plasma serum 15 minutes after administration. Administration of B I09 to CLL tumor-bearing mice suppress leukemic progression by inducing apoptosis and do not cause systemic toxicity.
体外研究：
B I09 is an IRE-1 RNase inhibitor, with an IC50 of 1230 nM. Treatment of CLL cells with this inhibitor (B I09) mimick XBP-1 deficiency, including upregulation of IRE-1 expression and compromised BCR signaling. B I09 is highly effective in inhibiting splicing of XBP1 mRNA in human WaC3 cells and the expression of XBP-1s in LPS stimulated B cells.
B I09 is an IRE-1 RNase inhibitor, with an IC50 of 1230 nM.
体内研究：
B I09 has a halflife of approximately 1.5 hours and reaches its peak concentration of approximately 39 μM in mouse plasma serum 15 minutes after administration. Administration of B I09 to CLL tumor-bearing mice suppress leukemic progression by inducing apoptosis and do not cause systemic toxicity.
体外研究：
B I09 is an IRE-1 RNase inhibitor, with an IC50 of 1230 nM. Treatment of CLL cells with this inhibitor (B I09) mimick XBP-1 deficiency, including upregulation of IRE-1 expression and compromised BCR signaling. B I09 is highly effective in inhibiting splicing of XBP1 mRNA in human WaC3 cells and the expression of XBP-1s in LPS stimulated B cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备